• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 5:02:49 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care
    Get the next $PLSE alert in real time by email
    SC 13G/A 1 tm21900d3_sc13ga.htm SC 13G/A

     

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    PULSE BIOSCIENCES, INC.

     

    (Name of Issuer)

     

    Common Stock, Par Value $0.001 Per Share

     

    (Title of Class of Securities)

     

    74587B 10 1

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 5 

     

     

    CUSIP No. 76118L 10 2 13G Page  2  of  5  Pages

     

    1

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Peter A. Appel 

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ¨

    (b) x

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED

    BY
    EACH
    REPORTING
    PERSON

     WITH:

     

    5

    SOLE VOTING POWER

     

    1,205,065 

    6

    SHARED VOTING POWER

     

    0 

    7

    SOLE DISPOSITIVE POWER

     

    1,205,065 

    8

    SHARED DISPOSITIVE POWER 

     

    0 

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

      

    1,205,065 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.75% 

    12

    TYPE OF REPORTING PERSON*

     

    IN 

      

    *SEE INSTRUCTION BEFORE FILLING OUT

     

     Page 2 of 5 

     

     

    Item 1(a)Name of Issuer:

     

    Pulse Biosciences, Inc.

     

    Item 1(b)Address of Issuer's Principal Executive Offices:

     

    849 Mitten Road
    Suite 104

    Burlingame, CA 94010

     

    Item 2(a)Name of Person Filing:

     

    This statement is filed by Peter Appel with respect to shares of Common Stock, $0.001 par value per share (“Shares”), of the Issuer beneficially owned thereby.

     

    Item 2(b)Address or Principal Business Office:

     

    The address of the principal business office of Mr. Appel is 3505 Main Lodge Drive, Coconut Grove, FL 33133.

     

    Item 2(c)Citizenship:

     

    Mr. Appel is a United States citizen.

     

    Item 2(d)Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e)CUSIP Number:

     

    74587B 10 1

     

    Item 3Not Applicable

     

    Item 4Ownership:

     

    The percentages used herein are calculated based upon 25,341,540 Shares issued and outstanding as of November 2, 2020 as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.

     

    As of the close of business on December 31, 2020:

    (a) Amount beneficially owned: 1,205,065

    (b) Percent of class: 4.75%

    (c)(i) Sole power to vote or direct the vote: -1,205,065-

    (ii) Shared power to vote or direct the vote: -0-

    (iii) Sole power to dispose or direct the disposition: -1,205,065-

    (iv) Shared power to dispose or direct the disposition: -0-

     

     Page 3 of 5 

     

     

    Item 5Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the

    following. x

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person:

     

    Not Applicable

     

    Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

    Not Applicable

     

    Item 8Identification and Classification of Members of the Group:

     

    Not Applicable

     

    Item 9Notice of Dissolution of Group:

     

    Not Applicable

     

    Item 10Certification:

     

    By signing below the signatory certifies that, to the best of his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 

     

     Page 4 of 5 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021

     


    PETER A. APPEL

     

    /s/ Peter A. Appel                                 

    Name: Peter A. Appel

     

     

     Page 5 of 5 

     

     

    Get the next $PLSE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLSE

    DatePrice TargetRatingAnalyst
    2/10/2022$43.00 → $20.00Buy
    HC Wainwright & Co.
    11/16/2021$46.00 → $43.00Buy
    HC Wainwright & Co.
    7/27/2021$28.00Overweight
    Stephens & Co.
    More analyst ratings

    $PLSE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming BofA Securities 2025 Health Care Conference in Las Vegas. Pulse Biosciences' Management is scheduled to present on Wednesday, May 14, 2025, at 5:00 pm PT. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as we

      5/6/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on April 21, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to 19,500 shares of Company common stock. The Company's independent

      4/25/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously

      2/10/22 6:14:40 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously

      11/16/21 9:11:22 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Stephens & Co. initiated coverage on Pulse Biosciences with a new price target

      Stephens & Co. initiated coverage of Pulse Biosciences with a rating of Overweight and set a new price target of $28.00

      7/27/21 5:53:59 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zanganeh Mahkam exercised 60,242 in-the-money shares at a strike of $11.00, increasing direct ownership by 9% to 725,395 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      2/11/25 6:20:57 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Laviolette Paul A

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      1/13/25 7:45:33 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Former President and CEO Barrett Burke Thomas sold $871,000 worth of shares (50,000 units at $17.42), decreasing direct ownership by 44% to 63,172 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/20/24 5:00:42 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

      Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

      2/4/25 8:00:00 AM ET
      $AXTA
      $PLSE
      $TFX
      Paints/Coatings
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

      Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

      10/30/24 4:02:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

      Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

      8/12/24 4:01:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 8:02:46 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 6:05:11 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/13/24 7:30:48 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Pulse Biosciences Inc

      10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 5:24:22 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      5/8/25 4:22:58 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Pulse Biosciences Inc

      10-K/A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

      4/30/25 9:08:54 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Financials

    Live finance-specific insights

    See more
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-717-1738 or 1-646-307-1865. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelect

      4/24/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation technology for the treatment of benign thyroid nodules at the North American Society for Interventional Thyroidology Annual Meeting. Advanced pilot program optimizing therapy delivery with 8 centers in the U.S. that are expected to begin commercial

      3/27/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $PLSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Pulse Biosciences Inc

      SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

      7/8/24 3:30:25 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/14/23 7:21:15 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

      SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

      12/4/23 5:18:06 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care